↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

132 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
4 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
5 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
6 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
7 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
8 Adrenergic signaling in cardiomyocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
9 African trypanosomiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
10 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
14 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
15 Allograft rejection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
16 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
17 Alzheimer disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
18 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
19 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
20 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
21 Amoebiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
22 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
23 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
24 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
25 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
26 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
27 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
28 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
29 Antifolate resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
30 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
31 Antigen processing and presentation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
32 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
33 Apoptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
34 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
35 Asthma 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
36 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
37 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
38 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
39 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
40 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
41 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
42 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
43 Bladder cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
44 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
45 Breast cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
46 Breast cancer 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
47 Breast cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
48 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
49 C-type lectin receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
50 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
51 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
52 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
53 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
54 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
55 Calcium signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
56 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
57 Calcium signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
58 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
59 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
60 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
61 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
62 Calcium signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
63 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
64 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
65 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
66 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
67 cAMP signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
68 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
69 cAMP signaling pathway 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
70 Cellular senescence 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
71 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
72 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
73 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
74 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
75 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
76 cGMP-PKG signaling pathway 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
77 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
78 cGMP-PKG signaling pathway 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
79 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
80 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
81 Chagas disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
82 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
83 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
84 Complement and coagulation cascades 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 5件: 46, 70, 215, 227, 288 💬
85 Coronavirus disease - COVID-19 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
86 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
87 Cytokine-cytokine receptor interaction 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
88 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
89 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
90 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
91 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
92 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
93 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D00603 💬 Timolol 2件: 157, 227 💬
94 Dilated cardiomyopathy 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
95 Dilated cardiomyopathy 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
96 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
97 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
98 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
99 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
100 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
101 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
102 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
103 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
104 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
105 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
106 Endocrine and other factor-regulated calcium reabsorption 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
107 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
108 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
109 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
110 Endocrine resistance 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
111 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
112 Epstein-Barr virus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
113 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
114 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
115 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
116 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
117 Estrogen signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
118 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
119 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
120 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
121 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
122 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
123 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
124 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
125 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
126 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
127 Focal adhesion 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
128 FoxO signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
129 Gap junction 💬
 1件: ADRB1 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
130 Gap junction 💬
 1件: ADRB1 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
131 Gap junction 💬
 1件: ADRB1 💬 D00378 💬 Timolol 2件: 157, 227 💬
132 Gap junction 💬
 1件: ADRB1 💬 D00603 💬 Timolol 2件: 157, 227 💬
133 Gap junction 💬
 1件: ADRB1 💬 D08600 💬 Timolol 2件: 157, 227 💬
134 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
135 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
136 Gastric acid secretion 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
137 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
138 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
139 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
140 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
141 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
142 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
143 GnRH secretion 💬
 1件: ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
144 GnRH secretion 💬
 1件: ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
145 GnRH secretion 💬
 1件: ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
146 GnRH secretion 💬
 1件: ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
147 Graft-versus-host disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
148 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
149 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
150 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
151 Hematopoietic cell lineage 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
152 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
153 Hepatitis B 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
154 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
155 Hepatitis C 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
156 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
157 Herpes simplex virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
158 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
159 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
160 HIF-1 signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
161 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
162 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
163 Human cytomegalovirus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
164 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
165 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
166 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
167 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
168 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
169 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
170 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
171 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
172 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
173 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
174 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
175 Human papillomavirus infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
176 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
177 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
178 Human papillomavirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
179 Human T-cell leukemia virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
180 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
181 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
182 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
183 Hypertrophic cardiomyopathy 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
184 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
185 IL-17 signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
186 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
187 Inflammatory bowel disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
188 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
189 Influenza A 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
190 Influenza A 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 5件: 46, 70, 215, 227, 288 💬
191 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
192 Insulin resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
193 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
194 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
195 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
196 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
197 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
198 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
199 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
200 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
201 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
202 Legionellosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
203 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Leishmaniasis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
205 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
206 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
207 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
208 Malaria 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
209 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
210 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
211 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
212 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
213 MAPK signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
214 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
215 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
216 MAPK signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
217 Measles 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
218 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
219 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
220 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
221 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
222 mTOR signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
223 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
224 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
225 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
226 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
227 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
228 Necroptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
229 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
230 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
231 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
232 Neuroactive ligand-receptor interaction 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
233 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
234 Neuroactive ligand-receptor interaction 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
235 Neuroactive ligand-receptor interaction 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 5件: 46, 70, 215, 227, 288 💬
236 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
237 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
238 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
239 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
240 NOD-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
241 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
242 Non-alcoholic fatty liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
243 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
244 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
245 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
246 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
247 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
248 Osteoclast differentiation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
249 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
250 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
251 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
252 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
253 Pancreatic cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
254 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
255 Pathogenic Escherichia coli infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
256 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
257 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
258 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
259 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
260 Pathways in cancer 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
261 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
262 Pathways in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
263 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
264 Pathways in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
265 Pathways of neurodegeneration - multiple diseases 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
266 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
267 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
268 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
269 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
270 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
271 Pertussis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
272 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
273 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
274 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
275 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
276 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
277 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
278 Prion disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
279 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
280 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
281 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
282 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D00185 💬 Estriol 2件: 13, 227 💬
283 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D01986 💬 Estriol 2件: 13, 227 💬
284 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
285 Prolactin signaling pathway 💬
 2件: ESR1, ESR2 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
286 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
287 Proteoglycans in cancer 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
288 Proteoglycans in cancer 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
289 Proteoglycans in cancer 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
290 Proteoglycans in cancer 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
291 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
292 Proteoglycans in cancer 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
293 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
294 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
295 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
296 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
297 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
298 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
299 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
300 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
301 Ras signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
302 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
303 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
304 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
305 Regulation of lipolysis in adipocytes 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
306 Regulation of lipolysis in adipocytes 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
307 Regulation of lipolysis in adipocytes 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
308 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
309 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
310 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
311 Renal cell carcinoma 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
312 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
313 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
314 Renin secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
315 Renin secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
316 Renin secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
317 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
318 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
319 Rheumatoid arthritis 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
320 Rheumatoid arthritis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
321 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
322 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
323 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
324 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
325 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
326 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D00378 💬 Timolol 2件: 157, 227 💬
327 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D00603 💬 Timolol 2件: 157, 227 💬
328 Salivary secretion 💬
 2件: ADRB1, ADRB2 💬 D08600 💬 Timolol 2件: 157, 227 💬
329 Salivary secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
330 Salivary secretion 💬
 3件: ADRB1, ADRB2, ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
331 Salmonella infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
332 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
333 Shigellosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
334 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
335 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
336 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
337 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
338 Staphylococcus aureus infection 💬
 1件: PLG 💬 D01136 💬 Tranexamic acid 5件: 46, 70, 215, 227, 288 💬
339 Systemic lupus erythematosus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
340 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
341 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
342 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
343 T cell receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
344 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
345 TGF-beta signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
346 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
347 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
348 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
349 Th17 cell differentiation 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
350 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
351 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
352 Thermogenesis 💬
 1件: ADRB3 💬 D00483 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
353 Thermogenesis 💬
 1件: ADRB3 💬 D08443 💬 Propranolol 6件:  6 , 158, 167, 227, 278, 296 💬
354 Thermogenesis 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
355 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D00185 💬 Estriol 2件: 13, 227 💬
356 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D01986 💬 Estriol 2件: 13, 227 💬
357 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D00966 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
358 Thyroid hormone signaling pathway 💬
 1件: ESR1 💬 D08559 💬 Tamoxifen 4件:  2 , 86, 113, 227 💬
359 TNF signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
360 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
361 Toll-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
362 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
363 Toxoplasmosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
364 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
365 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
366 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
367 Tuberculosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
368 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
369 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
370 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
371 Type I diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
372 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
373 Type II diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
374 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
375 VEGF signaling pathway 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
376 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
377 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
378 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
379 VEGF signaling pathway 💬
 1件: VEGFA 💬 D05697 💬 Ranibizumab 4件: 34, 166, 227, 301 💬
380 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
381 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
382 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
383 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件:  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
384 Yersinia infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
385 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ